miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1. 2018

Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
The Key Laboratory of Major Autoimmune Diseases, The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Anhui Institute of Innovative Drugs, Institute for Liver Diseases, School of Pharmacy, Anhui Medical University, Hefei, China.

Alcoholic liver disease (ALD) is a global liver disease which characterized by liver inflammation, fatty liver, alcoholic hepatitis, or liver cirrhosis. Alcohol abuse is one of the main reasons for liver disease. Alcoholic fatty liver (AFL) disease is the early stage of ALD and associated with the excessive lipids accumulation in hepatocytes as well as oxidative stress. MicroRNA-203 (miR-203) is known to suppress the proliferation and metastasis of hepatocellular carcinoma, but the role in the progression of alcoholic liver disease is not clear and is warranted for further investigation. In the present study, we have found the expression of miR-203 is down-regulated in Gao-Binge alcoholic mice model and ethanol-induced AML-12 cell lines in vitro. Furthermore, over-expression of miR-203 decrease the lipids accumulation in liver and ethanol-induced AML-12 cells. Mechanistically, we identified that Lipin1 is a key regulator of hepatic lipid metabolism, and acts as a downstream target for miR-203. In summary, our results suggested that over-expression of miR-203 inhibited the liver lipids accumulation and the progression of AFL by targeting Lipin1.

UI MeSH Term Description Entries

Related Publications

Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
January 2020, Frontiers in pharmacology,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
October 2016, Cell death & disease,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
January 2013, Cell biochemistry and function,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
September 2018, European review for medical and pharmacological sciences,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
October 2020, Biochimica et biophysica acta. Molecular and cell biology of lipids,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
July 2019, European review for medical and pharmacological sciences,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
December 2020, JHEP reports : innovation in hepatology,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
January 2013, PloS one,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
May 2018, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Xiao-Yu Cheng, and Jun-Da Liu, and Xin-Yi Lu, and Xing Yan, and Cheng Huang, and Xiao-Ming Meng, and Jun Li
September 2018, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!